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Abstract 
Iron deficiency and related iron deficiency anaemia (IDA) are the most prevalent 
nutritional disorders worldwide. The standard treatment involves supple-
mentation with solid or liquid iron supplement preparations, usually based on a 
ferrous salt such as ferrous sulphate, ferrous fumarate, or ferrous gluconate. In 
the present study, we compared iron uptake and absorption from various solid 
and liquid iron supplement preparations currently available in the United 
Kingdom using the well-characterised human epithelial adenocarcinoma cell 
line Caco-2. Intracellular ferritin protein formation by the Caco-2 cell was con-
sidered an indicator of cellular iron uptake and absorption. We investigated the 
effects of formulation ingredients at a defined pH on iron uptake and absorption, 
and designed a novel two-stage dissolution-absorption protocol that mimicked 
physiological conditions. Our experiments revealed wide variations in the rate of 
dissolution between the various solid iron preparations. Conventional-release 
ferrous iron tablets dissolved rapidly (48 ± 4 mins to 64 ± 4 mins), whereas 
modified-released tablets and capsules took significantly longer to undergo 
complete dissolution (274 ± 8 to 256 ± 8 mins). Among the solid iron prepa-
rations, ferrous sulphate conventional-release tablets demonstrated the highest 
iron absorption, whereas modified-release ferrous preparations demonstrated 
uniformly low iron absorption, as compared to the control (P < 0.05). Taken 
together, our results demonstrate that there are wide-ranging variations in 
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dissolution times and iron uptake from oral iron preparations, with the physical 
characteristics of the preparation as well as the form of iron playing a key role. 
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Abbreviations 
DMT1, Divalent proton-coupled metal iron transporter; Dcytb, Duodenal cytochrome b; 
IDA, iron deficiency anaemia; NHS, National Health Service; OTC, over the counter. 
Introduction 
Iron is an essential mineral nutrient that has a key physiological role and is required for 
numerous functions such as oxygen transport, ATP production, and DNA replication. In 
normal healthy humans, the main source of iron loss is through shedding of skin and 
sloughed gastrointestinal mucosal cells [1]. In males this accounts for approximately 
1 mg/day, while it is higher in women due to menstruation-associated blood loss. Iron 
cannot be synthesised in the human body and is therefore acquired primarily from dietary 
sources. Assuming a normal human diet, 12–18 mg of iron is ingested daily, mostly in the 
ferric form (Fe3+) [2]. Due to physiological as well as dietary factors, only 1–2 mg of this 
amount undergoes absorption through the gut enterocyte to become available to the 
systemic circulation [2].  
During the digestion of food in the stomach, bound iron is liberated from its matrix via a 
combination of factors that include gastric acidity, enzymatic action, and the churning 
action of the stomach muscles established by the specialised oblique muscle layer, which 
is unique to the stomach [3]. The released iron is then available for absorption, which 
occurs predominantly in the duodenal segment of the small intestine [4]. 
Most dietary non-haem iron is in the insoluble ferric form which is first reduced to ferrous 
iron by the ferric reductase DcytB (duodenal cytochrome b) located on the brush border 
surface of duodenal enterocytes [5]. Divalent proton-coupled metal iron transporter 
(DMT1) then transports ferrous iron across the apical membrane into the enterocyte, 
where it is either complexed within the storage protein ferritin, or transported into 
circulation across the basolateral membrane via the transmembrane transporter ferroportin 
(Ireg1) [6]. Haem iron uptake occurs via an as yet unclarified mechanism which may 
involve the folate channel HCP1 [7]. The absorption process is sensitive to various factors, 
dietary and otherwise, that may impede this process leading to insufficient absorption and 
consequent iron deficiency [8]. 
According to the WHO, iron deficiency is the most common nutritional disorder affecting as 
much as 20% of the global population [9]. It arises when the body’s iron requirements are 
not met by dietary iron. Reduced iron delivery to target sites such as the liver parenchyma, 
bone marrow, and muscle myoglobin results in an impairment of iron-dependent functions 
such as erythropoiesis [1]. A decrease in the number of red blood cells may also be 
characterised by a smaller mean cell size (microcytic anaemia) [10]. The net outcome is 
decreased oxygen carrying capacity and consequent tissue hypoxia. Iron depletion and 
 Comparison of Iron Supplement Absorption in Caco-2 Cells 1125 
Sci Pharm. 2013; 81: 1123–1139 
deficiency in its mildest form is not particularly detrimental, however, progression to iron 
deficiency anaemia (IDA) or sideropenic anaemia can have severe physiological 
consequences [11]. IDA during pregnancy has particularly severe consequences and has 
been associated with preterm delivery, perinatal mortality, maternal postpartum 
depression, and impaired mental development and cognitive ability of the offspring [12].  
Treatment for iron deficiency and IDA is generally by means of oral iron supplements. 
Supplementation therapy can also be prescribed prophylactically in certain cases, e.g. for 
pregnant women, haemodialysis patients, and low birth weight infants. Intravenous iron 
administration is carried out in extreme cases such as significant blood loss or advanced 
malnutrition [13]. Oral iron supplementation preparations are available either as licensed 
preparations available under prescription by a medical practitioner as well as non-
prescription over the counter (OTC) preparations, or as dietary or food supplements. 
Ferrous sulphate (FeSO4), along with the ferrous salts, ferrous fumarate and ferrous 
gluconate, are the most common form of iron supplements currently in use [14]. In the 
United Kingdom (UK), ferrous sulphate tablets (200 mg), usually containing 65 mg of 
elemental iron, are most often the first choice for treatment of iron deficiency anaemia [14]. 
Iron supplements are presented either as solid or liquid preparations with several possible 
variations. 
In this study, we have used a modified dissolution absorption in vitro model developed in 
our laboratory which utilises the human intestinal Caco-2 cell to compare iron uptake 
absorption from various solid and liquid iron supplementation preparations that are 
currently available. To our knowledge, such a study has not been conducted previously. 
Materials and Methods 
Materials 
All chemicals were of the highest available purity grade or cell culture grade, and 
purchased from Sigma-Aldrich (Dorset, UK) unless otherwise stated. Caco-2 cells were 
purchased from European Collection of Cell Cultures (Catalogue no. 09042001, ECACC, 
Salisbury, UK). Ferritin ELISA kits (Product code S-22) were from Ramco (ATI Atlas, 
Chichester, UK) and the BCA protein assay kit (Product no. 23225) was from Pierce 
(Thermo Fisher Scientific, Northumberland, UK). Protease inhibitor cocktail (PIC, 
catalogue no. P8340) was from Sigma-Aldrich (Dorset, UK). Cell culture media, foetal calf 
serum (FCS), and reagents were from Invitrogen (Loughborough, UK) and Lonza (Slough, 
UK). Cell culture plates (6-well and 96-well) and flasks were from Nunc (Roskilde, 
Denmark). All other cell culture plasticwares were supplied by Corning (Amsterdam, The 
Netherlands). Solid and liquid iron preparations from the UK were purchased from Boots 
retail pharmacy (London, UK). A summary of all samples tested is provided in Table 1. All 
reagents used were prepared using ultrapure water (resistivity of 18.2 MΩ cm). Prior to 
use, all glassware and utensils was soaked in 10% hydrochloric acid (HCl) and rinsed with 
ultrapure water to remove any potential traces of residual minerals. 
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Tab. 1.  List of oral iron supplement preparations compared for dissolution testing and 
iron absorption. Test samples include solid and liquid preparations currently 
available in the United Kingdom. 
No Preparation Dosage 
from 
Trade name / 
Manufacturer 
Elemental 
Fe/dos 
(mg) 
Category 
1 Ferrous sulphate Tablet NA Almus 65 
Licenced/ 
non proprietary 
2 Ferrous fumarate Tablet Fersamal Goldshield 68 
Licenced/ 
non proprietary 
3 Ferrous gluconate Tablet NA Zanza 35 
Licenced/ 
proprietary 
4 Ferrous sulphate plus ascorbic acid 
Controlled 
release 
tablet 
Ferrograd C 
Teopharma 105 
Licenced/ 
non proprietary 
5 Ferrous fumarate plus minerals and vitamins 
Sustained 
release 
capsule 
Ferroglobin B12 
Vitabiotics 24 
Over the  
counter 
6 Ferrous gluconate plus folic acid Syrup 
Ferroglobin 
Vitabiotics 7.5 
Over the  
counter 
7 Ferrous gluconate plus ascorbic acid Syrup 
Floradix 
Salus 10 
Over the  
counter 
 
Methods 
Cell Culture 
Caco-2 cells were obtained at passage 20 and used experimentally between passages 30 
to 35. Stock cultures were maintained in 75 cm2 tissue culture flasks in complete medium 
(Dulbecco’s modified Eagle’s media (DMEM) - Glutamax®, pH 7.4 supplemented with 10% 
FCS, 1% antibiotic/antimycotic solution and 25 mM HEPES). The cells were cultured in an 
incubator at 37°C in an atmosphere of 95% air and 5% CO2 at constant humidity, replacing 
the medium every two days. Cells were seeded onto 6-well plates at an initial seeding 
density of 1 x 104 cells/cm2 for the dissolution absorption experiment. Parallel 6-well plates 
were also seeded similarly for the assessment of cell viability prior to the commencement 
of the uptake experiment and following completion. Caco-2 cells were differentiated to a 
fully matured gastrointestinal (GI) tract phenotype at day 14–15 post-seeding, at which 
time iron uptake experiments were commenced. 
In vitro Dissolution 
Dissolution conditions were simulated in vitro to replicate physiological conditions as 
closely as possible. Iron preparations were either solid (tablets or capsules) or liquid 
(syrup-based solutions) dosage forms. Tablets and capsules were further classified as 
conventional-release or modified-release as per formulation characteristics. HCl 0.1 M (pH 
1.2) pre-warmed to 37°C was used to simulate gastric conditions, and a phosphate buffer 
adjusted to pH 5.8 with 2-(N-Morpholino)ethanesulfonic acid (10 mM) pre-warmed to 37°C 
was used to simulate intestinal conditions. On the day of the experiment, the solid dosage 
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forms were placed into glass beakers containing 50 mls of simulated gastric or intestinal 
fluid, and stirred gently at 25 revolutions per minute (rpm) to simulate the peristaltic 
movements in the GI tract. Temperature was kept constant at 37°C. Liquid dosage forms 
were also added to the dissolution media solution and subjected to similar conditions. 
Aliquots from the dissolution media were withdrawn following complete dissolution 
(determined by visual monitoring) and used for the iron uptake experiment.  
In vitro Iron Release 
Iron release from the dosage forms was determined by carrying out dissolution 
experiments under the conditions specified in Ph.Eur.4/USP 26. Dissolution media (37°C, 
pH 1.2) was prepared as described in the previous section. Iron release was evaluated by 
withdrawing 1 ml aliquots at predetermined sampling intervals (15, 30, 60, 90, 120 mins) 
and replacing with the equivalent volume of fresh dissolution media. The sample aliquots 
were centrifuged at 13,000 rpm for 10 minutes at 4 °C and the supernatants were 
analysed for iron content. 
Iron Quantification 
Iron release was quantified using a modified ferrozine assay (15) developed in our 
laboratory. Briefly, sample aliquots (10 µl) were added to microcentrifuge tubes containing 
300 µl HCL (0.5 M). Iron standards were prepared using analytical grade FeSO4. Detection 
reagent (500 µl containing ferrozine 2 mM, neocuproine 2 mM) was added to all tubes. 
The tubes were covered with aluminium foil and incubated in the dark for 60 mins after 
which time equal volumes (280 µl) of the test and standard samples were pipetted into a 
96-well microplate in triplicate. Absorbance was read at 562 nm using a microplate reader 
(VersaMax, Molecular devices, USA) and the iron content in the test samples was 
calculated from the standard curve generated from the iron standards. Iron release (% iron 
content as per label claim) from the dosage forms was determined from these values. 
Iron Uptake and Absorption by Caco-2 Cells 
On day 13 post-seeding, growth media was aspirated, cells were washed three times with 
wash solution (140 mM NaCl, 5 mM KCl, 10 mM PIPES buffer, pH 6.7, 37°C), and were 
then incubated in serum-free MEM for 24 hours. On the day of the uptake experiments, 
test media were prepared by titrating MEM with 0.1 M HCl or 0.1 M NaOH to pH 5.8 
(representative of the physiological pH in the duodenum). Test media was then sterile-
filtered using a 0.2 µm filter unit and then buffered with 2-(N-Morpholino)ethanesulfonic 
acid (MES, 10 mM). FeSO4 solution was used as a reference standard and was prepared 
by dissolving ultrapure FeSO4 powder in 0.1 M HCl. Media (14 ml) was aliquoted into 
individual falcon tubes and varying volumes of samples from the dissoluted test and 
reference preparations were added to the test media to achieve a final concentration of 
20 µM elemental iron for each condition. The pH of the iron-enriched sample media was 
measured again and adjusted to 5.8, when required. The trypan blue exclusion assay was 
carried out in parallel 6-well plates prior to commencing the experiments to assess Caco-2 
cell viability. Briefly, cells were stained with trypan blue dye which selectively stains dead 
cells; these were then counted under a microscope and the percentage viability was 
calculated. The Caco-2 cells in test plates were washed three times with wash solution 
and then incubated with iron-enriched test media (2 ml per well, three wells per condition) 
for 2 hours at 37°C in a plate incubator rocking gently at 25 rpm. The test media was then 
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aspirated and the cells were washed twice with wash solution and finally with a removal 
solution (wash solution plus 5 µm Na hydrosulphite and 1 µm bathophenanthroline 
disulfonate) to remove any surface-bound iron [16]. Caco-2 cells were then incubated with 
fresh MEM for a further 24 hours in a cell culture incubator (37°C, 95% air and 5% CO2). 
Parallel 6-well plates were also incubated with test media (prepared as described above) 
and subjected to similar conditions (one well per condition). The Caco-2 cell viability in 
these plates was assessed at the completion of the experiment using trypan blue dye 
exclusion assay. 
Caco-2 Cell Harvesting 
The culture media was aspirated 24 hours after incubation and Caco-2 cells were washed 
twice with wash buffer. The cells were harvested by addition of 350 µl lysis buffer (50 mM 
NaOH supplemented with 1µg/ml protease inhibitor cocktail) per well for 40 minutes while 
rocking gently on a plate shaker (6 rpm). The temperature was standardised at 4 °C 
throughout the lysis protocol. Cells were then collected using a sterile cell scraper and the 
resultant lysate was pipetted into 0.5 ml microcentrifuge tubes. Each sample lysate was 
passed six times through a 1 ml syringe fitted with 25 gauge needles to reduce viscosity 
and ease sample handling. Samples were aliquoted into two equal batches and stored 
immediately at −20°C until further analysis. 
Analytical Methods (Ferritin ELISA and BCA) 
The total ferritin concentration of the cell lysates was determined using a spectro-
photometric ELISA kit following the manufacturer’s protocol with minor modifications. 
Frozen cell lysates were centrifuged for 10 minutes (13226 g, 4°C) and the resultant 
supernatant was measured in the assay. A standard curve was generated using the 
standards provided (0, 6, 20, 60, 200 ng standard/ml). Samples and standards (30 µl 
each) were loaded in triplicate onto a 96-well plate and the incubation steps were carried 
out as described in the protocol. Absorbance was determined at 490 and 630 nm using a 
microplate reader (VersaMax, Molecular devices, USA). The protein content of the Caco-2 
cells was determined using the Pierce BCA kit following the manufacturer’s protocol using 
the bovine serum albumin (BSA) stock (2 mg/ml) provided in the kit as the standard. All 
samples were assayed in duplicate. The ferritin concentration was standardised against 
the total protein concentration and ng ferritin/ mg protein was used as an indicator of iron 
uptake and absorption by the Caco-2 cells. 
Statistical Analysis 
Iron uptake experiments were carried out twice independently, with each treatment 
condition performed in triplicate. A mean of six replicates was calculated for each 
treatment. The data is presented as the mean ± SEM and the differences between 
samples were analysed via Tukey’s one-way ANOVA followed by Tukey’s post hoc test 
using Graphpad Prism software (Version 5.0). Results were considered significantly 
different if P < 0.05. 
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Results 
In this study, we compared the iron uptake from various oral iron preparations using an in 
vitro model that attempted to mimic physiological conditions. The most commonly 
prescribed classical iron preparations were evaluated.  
We first carried out an experiment to compare dissolution rates of the various test 
preparations. Since we were investigating conventional- as well as modified-release 
preparations, the dissolution experiments were carried out at pH 1.2 to recreate the gastric 
environment, as well as at pH 5.8, to recreate the environment in the small intestine. At 
time zero, the tablets or capsules were dropped into the dissolution medium, and the 
dissolution runs for each preparation were carried out in triplicate. All preparations were 
taken from at least two different batches. The dissolution vessels were constantly 
monitored to observe the dissolution profiles of the test preparations. Complete dissolution 
of the tablet or capsule as observed visually was taken as the experimental endpoint. 
Results of the dissolution experiments are shown in Table 2.  
At pH 1.2, the conventional-release tablets exhibited a rapid rate of dissolution while the 
modified-release tablets and capsules dissolved gradually and variably. Ferrous sulphate 
tablets (unbranded/Almus) dissolved the fastest (48 ± 4 mins) followed by ferrous fumarate 
(Fersamal/Goldshield, 57 ± 6 mins) and ferrous gluconate tablets (unbranded/Zanza 64 ± 
4 mins). The slowest rate of dissolution was demonstrated by ferrous fumarate sustained-
release capsules (Feroglobin/Vitabiotics, 274 ± 8 mins) and ferrous sulphate controlled-
release tablets (Ferrograd C/Teopharma, 256 ± 8 mins). Under simulated intestinal 
conditions (pH 5.8), the fastest dissolution time was observed for ferrous fumarate tablets 
(85 ± 9 mins), whereas ferrous fumarate controlled-release tablets (Ferrograd 
C/Teopharma) failed to dissolve completely even after 24 h. Ferrous fumarate sustained-
release capsules (Ferroglobin B12/Vitabiotics) demonstrated a mean dissolution time of 
388 ± 11 mins at pH 5.8. 
Tab. 2.  Mean dissolution time for oral iron preparations. Dissolution time (mins) for solid 
oral iron preparations was tested in simulated stomach (0.1 M HCL pH 1.2, 
37°C) and simulated intestinal (Phosphate buffer, pH 5.8, 37°C) conditions. 
Values are mean ± SEM (n = 3). 
No Preparation Dosage 
from 
Trade name / 
Manufacturer 
Dissolution time (mins, n=3) 
pH 1.2 pH 5.8 
1 Ferrous sulphate Tablet NA Almus 48 ± 4 362 ± 16 
2 Ferrous fumarate Tablet Fersamal Goldshield 57 ± 6 85 ± 9 
3 Ferrous gluconate Tablet NA Zanza 64 ± 4 208 ± 12 
4 Ferrous sulphate plus ascorbic acid 
Controlled 
release 
tablet 
Ferrograd C 
Teopharma 256 ± 8 – 
5 Ferrous fumarate plus minerals and vitamins 
Sustained 
release 
capsule 
Ferroglobin B12 
Vitabiotics 274 ± 8 388 ± 11 
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We also investigated time-dependent iron release characteristics from test preparations by 
carrying out a separate series of dissolution experiments under simulated gastric 
conditions. The iron release form test preparations at varying time points (15, 30, 60, 90, 
180 mins) were quantified using a colorimetric assay. Results are shown below in Fig.1. 
Initial iron release at the first time point (15 min) was highest from the ferrous fumarate 
tablets (38.5%) while iron release at the final time point (180 min) was highest from the 
ferrous gluconate tablets (66.46%; see Fig. 1).  
Following the dissolution and release studies, we conducted iron uptake experiments. The 
trypan blue exclusion method was used to examine the Caco-2 cell viability prior to the 
commencement of the uptake experiments as well as following completion, to examine 
any detrimental effects of the formulation excipients on the Caco-2 cells. Viability above 
90% was observed in all cases (Data not shown). 
 
Fig. 1.  Iron release from oral iron preparations available in the United Kingdom. 
Dosage forms were subjected to in vitro dissolution (0.1M HCl pH 1.2, 37°C) 
and aliquots withdrawn at fixed intervals. Iron content in the sample aliquots 
was deteremined using a colorimetric iron quantification assay and used to 
calculate the % iron release. Values shown are mean of three readings for each 
test sample. 
Our aim was to compare the diverse range of preparations currently available in the UK 
using a defined and uniform set of conditions. The three most commonly used ferrous 
salts; ferrous sulphate, ferrous gluconate, and ferrous fumarate were tested in the form of 
conventional-release tablets. Ferrous sulphate plus ascorbic acid (Ferrograd C) and 
ferrous gluconate plus minerals and vitamins (Feroglobin B12) were included as 
representative modified-release and multivitamin preparations. Ferrous gluconate plus folic 
acid (Feroglobin B12) and ferrous gluconate plus ascorbic acid (Floradix) were included as 
representative syrup-based liquid preparations. These samples include both prescription 
and OTC iron supplement preparations. Ultrapure FeSO4 powder was included as a 
reference standard and absorption results were standardised to those of FeSO4 
(considered as 100%). Results are shown in Fig. 2. 
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Iron absorption from ferrous sulphate conventional-release tablets was significantly higher 
than any of the preparations evaluated (P<0.05), and equivalent to 41% of the FeSO4 
standard. Both the modified-released formulations containing ferrous sulphate plus 
ascorbic acid (Ferrograd C) and ferrous gluconate plus minerals and vitamins (Feroglobin 
B12) demonstrated low iron absorption. Syrup preparations containing ferrous gluconate 
plus folic acid (Feroglobin B12) and ferrous gluconate plus ascorbic acid (Floradix) also 
demonstrated relatively low iron absorption. Conventional-release ferrous sulphate 
therefore demonstrated the overall highest rate of iron uptake, whereas the lowest level of 
iron uptake was from ferrous sulphate plus ascorbic acid (Ferrograd C) modified-release 
tablets.  
 
Fig. 2.  Iron absorption from oral iron preparations available in the United Kingdom. 
Caco-2 cells were incubated with 20 µM iron from each of the test preparations. 
Iron absorption in terms of ferritin (ng/mg total protein) was determined by 
ELISA. Results are expressed as a % of ferrous sulphate control which is 
considered as 100%. Results are means ± SEM of 6 samples for each condition 
(P<0.05). The values are representative of three independent experiments. 
Discussion 
Iron supplementation is considered an effective strategy to counter anaemia, and iron 
preparations are some of the most commonly prescribed drugs [17]. Ferrous salts, first 
used in the 19th century, have remained the mainstay of iron therapy [1, 18]. The main 
advantages are low unit cost, thereby rendering them widely accessible. However, ferrous 
salts have a high propensity to cause side effects which generally lead to low patient 
compliance. Diarrhoea and constipation are commonly encountered by approximately 6% 
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of the patients, whereas 6–12% of the patients report nausea, vomiting, and gastric 
distress [19]. Most of these side effects are attributed to the fraction of iron that remains 
unabsorbed following ingestion and remains localised in the intestinal lumen. Some 
authors have attributed these side-effects to the irritation of the GI mucosa by the catalysis 
of free radicals from non-transferrin bound free iron [20]. 
In the present study, we compared iron absorption amongst several commercially 
available iron preparations. Representative products of the most commonly used iron 
preparations in the UK were evaluated in our study. We focused on these, as the 
preparations available in the UK undergo extensive regulatory procedures and also 
represent most iron preparations available globally. Very few studies in vivo or in vitro, 
however, have compared iron absorption from oral dosage forms and to our knowledge, 
no study has used a two-stage in vitro dissolution-absorption protocol. 
Iron absorption takes place principally in the duodenum region of the small intestine, and 
the human intestinal cell line Caco-2 has been well-characterised as a model for studying 
iron absorption in vitro [21]. Caco-2 cells exhibit the morphological characteristics of 
mature enterocytes and express most of the receptors involved in iron absorption, 
including DMT-1, DcytB, and Ireg1 (ferroportin), IRE1, and IRE2. Several studies have 
previously compared iron uptake from iron salts, whole foods, fruit juices, and infant 
formulas using the Caco-2-ferritin quantification model [22–26]. Most oral iron supplement 
preparations are however administered as dosage forms (tablets, capsules, syrups, or 
solutions) and include a number of active and inactive ingredients (e.g. binders, diluents, 
disintegrants) necessary for the formulation that may potentially have an influence on iron 
uptake and absorption. Active ingredients may include other minerals and vitamins such 
as ascorbic acid (vitamin C), which is often included in combination with iron as it is 
generally regarded as an enhancer of iron absorption [27]. In conditions that reflect a need 
for replacement therapy, such as during pregnancy and malnutrition, experts also 
recommend iron in combinations with other micronutrients such as folic acid and vitamin 
B12 [28]. In the case of liquid preparations such as syrups, additives such as flavourants 
and colourants are also added to increase presentation and palatability. Several iron 
syrup, solution, and elixir preparations contain fruit and plant juices or extracts. Fruit juices 
and vegetable extracts are rich in polyphenols; known inhibitors of iron absorption [29–31]. 
We therefore wanted to investigate the combined effect of the physical form of the 
preparation in combination with the iron source.  
Following ingestion, solid oral formulations undergo dissolution under the influence of the 
acidic pH of the stomach assisted by the peristaltic motion and segmentation of GI 
muscles. Dissolution is the rate-determining step for the absorption of various oral drugs, 
and dissolution rates vary widely, depending upon the nature of the formulation [32]. Fast-
dissolving tablets release iron quickly; however, this might lead to side effects due to 
excess free iron localisation/accumulation and consequent chemical irritation of the GI 
mucosa [33]. To counter this, slow- or modified-release tablets have been formulated. 
Modified-release tablets or capsules are pharmaceutical strategies to maintain a slow and 
gradual release of the active ingredient following ingestion, based on the rationale that iron 
released in such a manner is better tolerated as it would avoid overaccumulation and its 
consequent adverse effects. This is usually achieved by coating the tablet with a film, or by 
entrapping the active ingredient in a polymeric matrix, thereby causing it to release at a 
slow and gradual rate. Such iron preparations are relatively more expensive than 
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conventional tablets [33]. The physiological process of gastric emptying limits the relative 
amount of time that tablets and other solid dosage forms have available to them to 
undergo complete dissolution. Gastric emptying time for adult humans is between 3–6 h 
[34], and therefore if the tablet does not undergo complete dissolution within this period the 
residual undissolved fraction will be transported into the large intestine to be subsequently 
excreted. This would imply loss of a major proportion of the dosage form before the active 
ingredient can be fully released and available for absorption [35]. Regulatory bodies such 
as the UK National Health Service (NHS) have therefore recommended against the use of 
modified-release iron formulations [33].  
At present, there is no dissolution test indicated for iron preparations as per the British 
Pharmacopoeia (BP), while the United States Pharmacopoeia (USP) specifies a 
dissolution test only for ferrous gluconate tablets and capsules [36]. We developed a two-
step dissolution-absorption protocol that aims to replicate the temperature, pH, acidity, and 
mechanical conditions that the dosage forms encounter within the human stomach. Our 
protocol takes into consideration the effect of dissolution time, excipients, and variations in 
pH on iron absorption from oral preparations. 
Prior to our experiments, we carried out optimisation studies to evaluate dissolution time 
for all solid preparations being tested. HCL (0.1 M, pH 1.2) was used to simulate gastric 
fluid to mimic the pH environment of the stomach, and a phosphate buffer (pH 5.8) was 
used to simulate intestinal fluid to take into account the dissolution pattern of modified-
released preparations. Conventional fast-release tablets were found to dissolute 
completely in ~2 h (under gastric pH conditions), whereas modified-release tablets took 
significantly longer (~4 h). At intestinal pH conditions, the modified-release dosage forms 
demonstrated variable dissolution rates, with the controlled-release tablet Ferrograd C 
failing to undergo complete dissolution even after 24 hours. Our data is in agreement with 
a study by Bannerman and colleagues where dissolution profiles of various solid oral iron 
preparations were compared [36].  
We also examined iron release from the dosage forms during the dissolution process, and 
the results corresponded to our dissolution data. Our results indicated that the iron 
preparations appear to follow the predicted pattern of drug release as per their dosage 
form design i.e. the conventional-release tablet demonstrated rapid iron release while the 
controlled- and sustained-release formulations demonstrated a gradual release pattern 
over a longer period.  
After the iron preparations were subjected to dissolution, aliquots were withdrawn, the 
equivalent of 20 µM Fe final concentration, and were used for the iron uptake experiments. 
This concentration was selected based on optimisation experiments carried out in our 
laboratory, and is in agreement with several previous studies that have found this 
concentration to be optimum for iron uptake studies [25, 37]. 
Excipients are known to play either a facilitatory or inhibitory a role on drug absorption [38]; 
we therefore did not filter the samples, thus allowing us to study the effects of excipients 
on iron uptake in the Caco-2 cells. The pH of the treatment media was adjusted to pH 5.8, 
which is a representative pH in the distal duodenum and has been optimised by others 
[39]. Uptake experiments were standardised for 2 hours, which represents the physio-
logical transit time through the small intestine [40].  
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We measured intracellular ferritin concentrations as a measure of iron absorption in Caco-
2 cells. This method is very sensitive, has been well-characterised, and shows a good 
correlation with human absorption. Caco-2 cells synthesise ferritin in response to their iron 
status, as well as iron levels in their surrounding environment [37]. We therefore cultured 
the cells in media containing minimal amounts of iron 24 hours prior to the experiment to 
ensure minimal cellular ferritin formation prior to the uptake experiments. Under these 
conditions, Caco-2 cells demonstrate maximal iron uptake and therefore minute variations 
in iron uptake between the various samples can be measured accurately in terms of the 
ferritin formation [21]. Iron uptake studies can also be carried out by measuring 
intracellular total iron uptake using either atomic absorption spectroscopy or radio-labelled 
iron. These methods necessitate the requirement for complex instrumentation and 
specialised facilities. Some iron compounds and complexes cannot be labelled either 
intrinsically or extrinsically with iron radioisotopes. Ferritin measurement avoids these 
issues and also circumvents the problem of non-specific binding of free iron to the cell 
surface that might lead to inaccurate total cellular iron quantification. 
Our study has demonstrated that amongst the various iron preparations tested, 
conventional fast-release ferrous sulphate tablets demonstrate the highest iron absorption, 
whereas modified-release iron tablets uniformly had the lowest iron absorption. This is in 
agreement with other studies that have also shown modified-release or iron formulations to 
have poor bioavailability [36, 40]. Equal doses of elemental iron (20 µm) from each 
preparation were used in our uptake experiments, thus the variations in iron absorption 
between the various preparations cannot be attributed to the differences in iron content of 
each formulation. A possible explanation for the variability in iron absorption between the 
samples may be due to the formulation characteristics of the iron preparation form. 
Conventional-release iron tablets are formulated to release iron rapidly and contain fewer 
excipients. Modified-release preparations are relatively more complex preparations and 
include several excipients and additives. Certain excipients are included to enhance 
absorption of the active ingredient [41]. However, excipients can also have a detrimental 
effect on uptake and absorption, by entrapping the active ingredient in a matrix, thereby 
making it unavailable for cellular uptake [42, 43]. The liquid iron preparations tested are 
also formulated with numerous excipients, mainly to improve palatability and appearance. 
Certain additives present in these preparations are known to inhibit iron absorption. For 
example, the liquid preparation Floradix is formulated in a syrup base that includes 29% 
fruit juice including grape and cherry juice, which may inhibit iron absorption due to their 
high polyphenol content [31]. Free FeSO4 solution, included as a reference standard in our 
experiments, demonstrated the highest iron uptake. Our results therefore indicate that the 
physical forms of the preparation, as well as the iron form, have an influence on iron 
uptake and absorption from oral dosage forms.  
Comparison of iron absorption from oral dosage forms can be a valuable tool in assessing 
the efficacy of oral iron preparations. Iron supplementation is considered a convenient and 
economical measure to counter iron deficiency and its consequences, and a wide variety 
of solid and liquid iron preparations are available either as prescription or OTC supplement 
products. This study did not seek to challenge the fundamental strategy, but rather to 
explore any variations in iron release and uptake that might exist between the various 
preparations that could lead to less favourable outcomes of iron supplementation therapy.  
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We believe that this study provides important insights into the physiological process of iron 
absorption from oral iron preparations and may therefore assist in the development of 
novel preparations that deliver requisite amounts of iron, while limiting adverse effects. Our 
future studies will determine iron absorption from oral preparations in the presence of food 
substances and will evaluate correlations with clinical data. 
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